PRESS-RELEASE filed Aug 12, 2026 at 07:00 ET
TScan Therapeutics reported Q2 2026 EPS of -$0.23, a 15% miss vs consensus of -$0.20, and revenue of $1.1M, sharply down 66% YoY from $3.1M due to timing of Amgen collaboration activities. The net loss narrowed to $30.4M from $37.0M, but cash burn remains high with cash runway only into Q2 2027, pressured by upcoming debt amortization. Positive clinical data from the Phase 1 ALLOHA study and first patient dosed in the Phase 3 ALLOHA-2 trial provide pipeline catalysts, but the financial miss and cash constraints dominate the near-term outlook.